Publications
2018
Aggressive B-cell lymphomas in patients with myelofibrosis receiving JAK1/2 inhibitor therapy.
Porpaczy E,
Tripolt S,
Hoelbl-Kovacic A,
Gisslinger B,
Bago-Horvath Z,
Casanova-Hevia E,
Clappier E,
Decker T,
Fajmann S,
Fux DA,
Greiner G,
Gueltekin S,
Heller G,
Herkner H,
Hoermann G,
Kiladjian JJ,
Kolbe T,
Kornauth C,
Krauth MT,
Kralovics R,
Muellauer L,
Mueller M,
Prchal-Murphy M,
Putz EM,
Raffoux E,
Schiefer AI,
Schmetterer K,
Schneckenleithner C,
Simonitsch-Klupp I,
Skrabs C,
Sperr WR,
Staber PB,
Strobl B,
Valent P,
Jaeger U,
Gisslinger H,
Sexl V.
Blood. 2018 Aug 16;132(7):694-706. doi: 10.1182/blood-2017-10-810739. Epub 2018 Jun 14.
2018
Correction: The ratio of STAT1 to STAT3 expression is a determinant of colorectal cancer growth.
Nivarthi H,
Gordziel C,
Themanns M,
Kramer N,
Eberl M,
Rabe B,
Schlederer M,
Rose-John S,
Knösel T,
Kenner L,
Freund P,
Aberger F,
Han X,
Kralovics R,
Dolznig H,
Jennek S,
Friedrich K,
Moriggl R.
Oncotarget. 2018 Sep 18;9(73):33865. doi: 10.18632/oncotarget.26156. eCollection 2018 Sep 18.
2018
Correction: Increased survival and cell cycle progression pathways are required for EWS/FLI1-induced malignant transformation.
Javaheri T,
Kazemi Z,
Jan Pencik,
Pham HTT,
Kauer M,
Noorizadeh R,
Sax B,
Nivarthi H,
Schlederer M,
Maurer B,
Hofbauer M,
Aryee DNT,
Wiedner M,
Tomazou EM,
Logan M,
Hartmann C,
Tuckermann JP,
Kenner L,
Mikula M,
Dolznig H,
Üren A,
Richter GH,
Grebien F,
Kovar H,
Moriggl R.
Cell Death Dis. 2018 Jul 23;9(8):800. doi: 10.1038/s41419-018-0773-9.
2018
LZTR1 is a regulator of RAS ubiquitination and signaling.
Bigenzahn JW,
Collu GM,
Kartnig F,
Pieraks M,
Vladimer GI,
Heinz LX,
Sedlyarov V,
Schischlik F,
Fauster A,
Rebsamen M,
Parapatics K,
Blomen VA,
Müller AC,
Winter GE,
Kralovics R,
Brummelkamp TR,
Mlodzik M,
Superti-Furga G.
Science. 2018 Nov 15. pii: eaap8210. doi: 10.1126/science.aap8210. [Epub ahead of print]
2018
Low-burden TP53 mutations in chronic phase of myeloproliferative neoplasms: association with age, hydroxyurea administration, disease type and JAK2 mutational status.
Kubesova B,
Pavlova S,
Malcikova J,
Kabathova J,
Radova L,
Tom N,
Tichy B,
Plevova K,
Kantorova B,
Fiedorova K,
Slavikova M,
Bystry V,
Kissova J,
Gisslinger B,
Gisslinger H,
Penka M,
Mayer J,
Kralovics R,
Pospisilova S,
Doubek M.
Leukemia. 2018 Feb;32(2):450-461. doi: 10.1038/leu.2017.230. Epub 2017 Jul 24.
2018
Chromothripsis in acute myeloid leukemia: biological features and impact on survival.
Fontana MC,
Marconi G,
Feenstra JDM,
Fonzi E,
Papayannidis C,
Ghelli Luserna di Rorá A,
Padella A,
Solli V,
Franchini E,
Ottaviani E,
Ferrari A,
Baldazzi C,
Testoni N,
Iacobucci I,
Soverini S,
Haferlach T,
Guadagnuolo V,
Semerad L,
Doubek M,
Steurer M,
Racil Z,
Paolini S,
Manfrini M,
Cavo M,
Simonetti G,
Kralovics R,
Martinelli G.
Leukemia. 2018 Feb 23. doi: 10.1038/s41375-018-0035-y. [Epub ahead of print]
2018
STAT5BN642H is a driver mutation for T cell neoplasia.
Pham HTT,
Maurer B,
Prchal-Murphy M,
Grausenburger R,
Grundschober E,
Javaheri T,
Nivarthi H,
Boersma A,
Kolbe T,
Elabd M,
Halbritter F,
Pencik J,
Kazemi Z,
Grebien F,
Hengstschläger M,
Kenner L,
Kubicek S,
Farlik M,
Bock C,
Valent P,
Müller M,
Rülicke T,
Sexl V,
Moriggl R.
J Clin Invest. 2018 Jan 2;128(1):387-401. doi: 10.1172/JCI94509. Epub 2017 Dec 4.
2017
Low-burden TP53 mutations in chronic phase of myeloproliferative neoplasms: association with age, hydroxyurea administration, disease type and JAK2 mutational status.
Kubesova B,
Pavlova S,
Malcikova J,
Kabathova J,
Radova L,
Tom N,
Tichy B,
Plevova K,
Kantorova B,
Fiedorova K,
Slavikova M,
Bystry V,
Kissova J,
Gisslinger B,
Gisslinger H,
Penka M,
Mayer J,
Kralovics R,
Pospisilova S,
Doubek M.
Leukemia. 2017 Jul 24. doi: 10.1038/leu.2017.230. [Epub ahead of print]
2017
Mutations in myeloproliferative neoplasms - their significance and clinical use.
Schischlik F,
Kralovics R.
Expert Rev Hematol. 2017 Nov;10(11):961-973. doi: 10.1080/17474086.2017.1380515. Epub 2017 Sep 25.
2017
Parallel genome-wide screens identify synthetic viable interactions between the BLM helicase complex and Fanconi anemia.
Moder M,
Velimezi G,
Owusu M,
Mazouzi A,
Wiedner M,
Ferreira da Silva J,
Robinson-Garcia L,
Schischlik F,
Slavkovsky R,
Kralovics R,
Schuster M,
Bock C,
Ideker T,
Jackson SP,
Menche J,
Loizou JI.
Nat Commun. 2017 Nov 1;8(1):1238. doi: 10.1038/s41467-017-01439-x.